Treatment of nontuberculous mycobacterial pulmonary disease: An official ats/ers/escmid/idsa clinical practice guideline: Clinical Infectious Diseases

C.L. Daley, J.M. Iaccarino, C. Lange, E. Cambau, Jr. Wallace R.J., C. Andrejak, E.C. Böttger, J. Brozek, D.E. Griffith, L. Guglielmetti, G.A. Huitt, S.L. Knight, P. Leitman, T.K. Marras, K.N. Olivier, M. Santin, J.E. Stout, E. Tortoli, J. Van Ingen, D. WagnerK.L. Winthrop

Research output: Contribution to journalArticlepeer-review

Abstract

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases. © The Author(s) 2020.
Original languageEnglish
Pages (from-to)E1-E36
JournalClin. Infect. Dis.
Volume71
Issue number4
DOIs
Publication statusPublished - 2020

Keywords

  • Mycobacterium abscessus
  • Mycobacterium avium complex
  • Mycobacterium kansasii
  • Mycobacterium xenopi
  • Nontuberculous
  • amikacin
  • azithromycin
  • clarithromycin
  • isoniazid
  • macrolide
  • rifampicin
  • streptomycin
  • adverse drug reaction
  • antibiotic sensitivity
  • Article
  • atypical mycobacteriosis
  • doublet chemotherapy
  • drug monitoring
  • human
  • laboratory diagnosis
  • lung tuberculosis
  • Mycobacterium xenopei
  • nonhuman
  • practice guideline
  • priority journal
  • species identification
  • systematic review (topic)
  • treatment response
  • triplet chemotherapy

Fingerprint Dive into the research topics of 'Treatment of nontuberculous mycobacterial pulmonary disease: An official ats/ers/escmid/idsa clinical practice guideline: Clinical Infectious Diseases'. Together they form a unique fingerprint.

Cite this